Cagrilintide
Metabolic In trials Human trials
A long-acting copy of amylin, a hormone released with insulin after meals. A fatty-acid side chain lets it bind albumin and last about a week. It acts on amylin and calcitonin receptors in the brainstem to increase fullness and slow stomach emptying, and is studied for weight management, often together with semaglutide.
Why people take it
What studies report
- Around 10-11% body weight loss over a year on its own in phase 2
- About 20%+ when combined with semaglutide (CagriSema) in phase 3
- Reduced appetite and slower gastric emptying
In practice Unapproved use
- Appearing through compounding pharmacies and research suppliers ahead of approval
- Stacked with semaglutide or tirzepatide, mirroring the CagriSema trials
Science hasn't caught up: Being used in combination ahead of the approval its combination trials are still seeking.
Reported real-world use, not evidence and not a recommendation.
Worth knowing: Nausea and vomiting are common. Still investigational.
Status: In late-stage clinical trials. Not approved as of this writing.
- Route
- Subcutaneous injection, from reconstituted lyophilised powder
- Molecular weight
- ≈4409 g/mol
- CAS
- 1415456-99-3
- Available as
- 5 mg, 10 mg
Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.